Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.
I'm expecting the results of G4S very soon! Remember the g4s operative will fit a LeakBot for free in the trial! Big incentive on top of the already big incentives!
It's going to be a no brainer!
Great finish on the charts in a very difficult market! Nice bottom formed.
Talking to the company sounds like plenty of things going on reading between the lines!
This is a dropportinity!
https://twitter.com/MylesMcNulty/status/1709192026980339834?t=kZxzZGWay5W-sUql7Vg2RA&s=19
Https://twitter.com/RAH00084/status/1709110634858590517?t=LfItfokRowDUYGrgWeDCXA&s=19
Https://twitter.com/BSF_Enterprise/status/1709106006431764861?t=Lfeqkgv4kFeZqPrw5uQVbg&s=19
Https://twitter.com/RAH00084/status/1708781493445607907?t=I8PznO8VACIG-1wkF03fCg&s=19
Https://twitter.com/JamesMelville/status/1708762635808772302?t=8FxDig0gL0j70_CMSGQIZw&s=19
Https://twitter.com/LaurenWitzkeDE/status/1708254438148702686?t=gKDq97RdnB8FG7nFDmqD1g&s=19
There won't be any water company on the planet that could possibly resist ondo's solution!
29 September 2023
Avacta Group plc
("Avacta", the "Group" or the "Company")
Director/PDMR Shareholdings
Avacta Group plc (AIM: AVCT), a life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics, announces it has granted a total of 2,500,000 options over ordinary shares of 10p each ("Ordinary Shares") to certain directors of the Company (the "Options").
These Options were granted under the Company's Long term Incentive Plan, Avacta Group plc Executive Share Option Scheme as set out below:
Director
Position
Number of Options Granted
Exercise Price
Alastair Smith
CEO
1,250,000
10p
Tony Gardiner
CFO
1,250,000
10p
The vesting conditions are based on the share price performance of the Company over the three year period up to 31 December 2025 relative to the performance of the FTSE AIM All Share Index during the same period.
Following these awards, the total number of Options held by the directors were as set out below:
Director
Position
Number of Options held
Alastair Smith
CEO
6,241,426
Tony Gardiner
CFO
2,828,384
Dr Eliot Forster, Chairman of Avacta Group plc said:
"Following the completion of the 2020 LTIP award period and the significant progress made within the Group during the year, I am pleased to confirm that the Remuneration Committee has been able to conclude the changes to the equity arrangements of Alastair and Tony. These arrangements continue to align the interest of the Executive Directors with the longer-term share price performance interests of our shareholders."
-Ends-
This is looking like an even better business than 6 months ago and it was very compelling then!
No signs of growth slowing for years matter what the economic climate.
Is growth speeding up????
Once our revenue run rate surpasses £50 000 000 (soon) this will no longer be seen as a micro stock and a whole new wave of institutional money will flood in!
Yes, partly that. There was a sell-off in technology as the Nasdaq broke down and so the whole sector suffered.
However the Nasdaq has been on a tear and AIM has been falling so any AIM technology stocks sell-off will be fleeting.
That's my take but there could be other factors. Other AIM technology stocks in my list sold off too today.
I'm relatively bullish. I can see a bottom forming but we do have the worst leaders both political and administrative probably ever? (They are trying to fight inflation but keep spending and are restricting supply chains which is all contradictory).
Traders getting out on news which was known to the market. Frustrating sure but happens all the time.
Aim market looking a bit better so bodes well for when interest rates peak. It's been a long time coming but that just means the re rate will be bigger.
Bsfa pretty pleased as they should be. Endorsement as well as the money is the big story!
https://twitter.com/BSF_Enterprise/status/1703657606890262908?t=N_rD6Msh7DFglyBs6OLDIw&s=19
Https://twitter.com/MylesMcNulty/status/1701157156358078935?t=Q99TBVfB_XzOiou14IyYQw&s=19
Che Connon, Chief Executive of 3DBT and Managing Director of BSF, said: "BSF has made huge progress in its first year as a listed company, with 3D Bio-Tissues achieving significant technical and commercial milestones. We have a clear plan and are well funded to continue this momentum in the coming year by increasing sales and driving the development of our flagship City-Mix™ product. We intend to add additional growth through the creation of a collaborative ecosystem of tissue engineering companies, through M&A and partnerships, and we are extremely excited about the opportunities this will afford us as we continue to grow our commercial presence across the industry."